Hamps Bio Limited
Listing performance
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Issue details
- IPO date
- 13 Dec 2024 – 17 Dec 2024
- Listing date
- 20 Dec 2024
- Face value
- ₹1 per share
- Issue price
- ₹51 per share
- Lot size
- 2,000 shares
- Issue type
- Fixed Price issue
- Listing at
- BSE
- Total issue size
- ₹6.22 Cr
- Market cap at offer price
- ₹22.22 Cr
- Promoter holding
- 100.00% → 71.99% pre-issue → post-issue
- ISIN
- INE0QBD01018
- Registrar
- Bigshare Services Pvt.Ltd.
- Lead managers
- Marwadi Chandarana Intermediaries Brokers Pvt.Ltd.
- Registered office
- 2900/112, GIDC, Near Atul Limited, Ankleshwar, Gujarat
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Market maker | 62,000 | — | — |
Application size
Minimum 2,000 shares per lot, in multiples, at ₹51
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 2,000 | ₹1,02,000 |
| S-HNI (min) | 2 | 4,000 | ₹2,04,000 |
| S-HNI (max) | 9 | 18,000 | ₹9,18,000 |
| B-HNI (min) | 10 | 20,000 | ₹10,20,000 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Valuation and performance
Valuation at offer price
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 1.60 | 1.34 |
| P/E (×) | 31.88 | 38.06 |
| Price to book (×) | 2.96 | — |
| Market cap | — | ₹22.22 Cr |
Key performance indicators
- Return on net worth
- 14.84%
- ROCE
- 18.31%
- Debt / equity
- 0.31
- PAT margin
- 7.73%
- NAV per share
- ₹17.22
- Price to book
- 2.96
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Hamps Bio Limited
Hamps Bio Limited, incorporated in January 2007 and converted to a public limited company in 2023, operates in two primary segments: ethical marketing and distribution of pharmaceutical formulation products under the brand 'Hamps' across tablets, syrups, capsules, injectables, oils, gels and powders; and manufacturing of freeze-dried and frozen products (FDFP) under the brand 'FzyEzy' including fruits, vegetables, herbs and flowers. The company sells pharmaceutical products primarily through a network of over 35 distributors covering 8 states and union territories in India, while FDFP products are distributed through over 50 distributor networks and e-commerce platforms including Amazon and Flipkart, reaching 6 countries and 22 states and union territories. As of October 31, 2024, the company offered a range of more than 180 different products across both segments, generating revenue of ₹426.67 Lakhs in the seven months ended October 31, 2024.
Company Analysis
from RHPHamps Bio Limited is an ethical pharmaceutical marketing and distribution company and freeze-dried/frozen food products manufacturer operating across multiple Indian states and international markets.
Hamps Bio Limited, incorporated in January 2007 and converted to a public limited company in 2023, operates in two primary segments: ethical marketing and distribution of pharmaceutical formulation products under the brand 'Hamps' across tablets, syrups, capsules, injectables, oils, gels and powders; and manufacturing of freeze-dried and frozen products (FDFP) under the brand 'FzyEzy' including fruits, vegetables, herbs and flowers. The company sells pharmaceutical products primarily through a network of over 35 distributors covering 8 states and union territories in India, while FDFP products are distributed through over 50 distributor networks and e-commerce platforms including Amazon and Flipkart, reaching 6 countries and 22 states and union territories. As of October 31, 2024, the company offered a range of more than 180 different products across both segments, generating revenue of ₹426.67 Lakhs in the seven months ended October 31, 2024.
Objects of the Issue
- Purchase of Plant and Machinery for FMCG Division ₹359.00 Lakhs p.23
- Enhancing the visibility and awareness of our brand ₹50.00 Lakhs p.23
- General corporate purposes ₹151.87 Lakhs p.23
- Purchase of plant & machinery for FMCG division ₹359.00 Lakhs p.80
- Enhancing the visibility and awareness of our brand ₹50.00 Lakhs p.80
- General corporate purposes ₹151.87 Lakhs p.80
- Capital Expenditure to meet growing demand of FDFP products - installation of new plant and machinery to increase processing and production capacity ₹359.00 Lakhs p.116
- Repayment of borrowings
- General corporate purposes
Issue Structure
- Total Issue
- Upto ₹622.20 Lakhs (12,20,000 Equity Shares at ₹51.00 each)
- Fresh Issue
- Upto ₹622.20 Lakhs (12,20,000 Equity Shares of face value ₹10/- each at ₹51.00 per share)
- Offer for Sale
- Not Applicable
- Price Band
- ₹51.00 per Equity Share (Fixed Price)
- Lot Size
- 2000 Equity Shares and in multiples thereof
- Face Value
- ₹10/- per Equity Share
Business Model
The company generates revenue through two segments: (1) Pharma segment - ethical marketing and distribution of pharmaceutical formulations through a distributor network covering primarily 8 states; (2) FDFP segment - manufacturing and distribution of freeze-dried and frozen products through distributors, e-commerce platforms and retail channels. For the seven months ended October 31, 2024, the Pharma segment contributed 49.60% of revenue from operations (₹211.64 Lakhs) while the FDFP segment contributed 50.40% (₹215.03 Lakhs).
Business Segments
SWOT Analysis
- • Established brand presence in pharmaceutical and FMCG segments(p.23)
- • Diversified product portfolio across multiple dosage forms and food products(p.23)
- • Multi-channel distribution reaching significant geographic and customer base(p.23)
- • Balanced revenue generation across business segments(p.23)
- • No significant product liability claims or operational disruptions in recent history(p.30)
- • Diversified product portfolio across two business segments(p.109)
- • Established distribution network across multiple states and e-commerce platforms(p.109)
- • Strong presence in FDFP with modern manufacturing and quality certifications(p.111)
- • International presence and export capabilities in FDFP segment(p.111)
- • Effective market coverage through organized sales team(p.110)
- • Expert leadership with 20+ years pharmaceutical experience(p.113)
- • Extensive distribution network with 50+ distributors and e-commerce presence(p.113)
- • Diversified product portfolio of 100+ pharma items and 80+ freeze-dried SKUs(p.119)
- • Strong customer relationships with 244 customers and long-term retention(p.114)
- • Geographic presence across 22 Indian states and 6 export countries(p.115)
- • Strong brand recognition with 39 registered trademarks(p.116)
- • ISO certifications for quality and food safety management(p.116)
- • Strong revenue growth with 10.11% CAGR and improving profitability(p.112)
- • Dependence on third-party contract manufacturers with no long-term agreements(p.29)
- • Concentrated manufacturing facility exposed to regional risks(p.30)
- • High dependence on top suppliers for raw materials without formal agreements(p.33)
- • Significant customer concentration in FMCG segment(p.33)
- • History of negative cash flows impacting operational flexibility(p.33)
- • Leased facilities without ownership of manufacturing or corporate premises(p.41)
- • Outstanding civil litigation with unascertained quantum of liability(p.28)
- • Heavy dependence on a limited number of contract manufacturers in Pharma segment(p.109)
- • Concentrated pharma revenue in single state(p.110)
- • Limited profitability and declining margins in recent periods(p.90)
- • Significant debt burden affecting financial flexibility(p.54)
- • High customer concentration with top 10 customers representing 61.57% of revenues(p.114)
- • Significant supplier concentration with top 10 suppliers representing 68.62% of purchases(p.125)
- • Geographic concentration with Gujarat accounting for 77.61% of domestic revenue(p.116)
- • Moderate capacity utilization at 66.67%(p.124)
- • Debt-to-Equity ratio of 0.37 indicates reliance on external financing(p.112)
- • Promoters have personally guaranteed cash credit facilities of Rs. 343.31 Lakhs(p.142)
- • Expansion into new geographic markets and customer segments(p.23)
- • Growth in e-commerce and online commerce channels in India(p.41)
- • Expansion of FMCG sector driven by favorable government policies and growing rural market(p.23)
- • Capacity expansion through new manufacturing equipment(p.23)
- • India's position as global pharmaceutical hub supporting growth(p.23)
- • Growth potential in Indian pharmaceutical market expansion(p.103)
- • E-commerce penetration for FMCG products(p.108)
- • Expanding rural and semi-urban FMCG consumption(p.105)
- • Growth in processed food market(p.106)
- • Expansion of manufacturing capacity for FDFP segment(p.81)
- • Brand building and market visibility initiatives(p.83)
- • Capital expenditure of Rs. 359 Lakhs to increase FDFP processing capacity(p.116)
- • Planned expansion from 22 states to pan-India and global markets(p.116)
- • Growing e-commerce penetration for FMCG freeze-dried products(p.113)
- • Plan to adopt solar energy to reduce power costs(p.117)
- • Strengthening marketing network through recruitment of qualified personnel(p.117)
- • Brand visibility expansion through international market entry(p.116)
- • Stringent pharmaceutical regulations and compliance requirements(p.30)
- • Significant geographic revenue concentration in Gujarat(p.36)
- • Exposure to increasing transportation costs and infrastructure limitations(p.36)
- • Dependence on power and water supply for manufacturing operations(p.36)
- • Intense competition from larger players and unorganized market(p.42)
- • Macroeconomic slowdown risks affecting Indian economy(p.49)
- • Regulatory risk from changes in food safety and environmental laws(p.30)
- • Foreign exchange control regulations and currency fluctuation risks(p.43)
- • Global financial instability and its impact on Indian markets(p.50)
- • Rising inflation pressuring profit margins(p.50)
- • Natural calamities and supply chain disruptions(p.51)
- • Geopolitical and security risks(p.51)
- • Regulatory and tax law uncertainties(p.51)
- • Infrastructure limitations impacting business operations(p.51)
- • Intense competition from domestic and international pharmaceutical players(p.126)
- • Regulatory compliance obligations under multiple pharmaceutical and food safety laws(p.130)
- • Price control under Drugs (Prices) Control Order 2013 for essential medicines(p.132)
- • Dependence on contract manufacturers for pharmaceutical products(p.125)
- • Commodity price and monsoon volatility affecting freeze-dried products(p.125)
- • Exposure to foreign exchange risk on export revenues(p.116)
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Herrik Shah | Promoter | 43.22% | — |
| Shrenik Shah | Promoter | 32.73% | — |
| Pallavi Shah | Promoter | 4.70% | — |
| Mitali Shah | Promoter | 1.02% | — |
| Herrik Shah HUF | Promoter | 7.32% | — |
| Shrenik Shah HUF | Promoter | 4.09% | — |
| Herrik Shah | Promoter/Chairman and Managing Director | 43.22% | 31.12% |
| Shrenik Shah | Promoter/Whole-time Director | 32.73% | 23.56% |
| Pallavi Shah | Promoter/Non-Executive Director | 4.70% | 3.38% |
| Mitali Shah | Promoter | 1.02% | 0.73% |
| Herrik Shah HUF | Promoter | 7.32% | 5.27% |
| Shrenik Shah HUF | Promoter | 4.09% | 2.94% |
| Mountbaton Shah HUF | Promoter Group | 4.75% | 3.42% |
| Bhavya Shah | Promoter Group | 2.04% | 1.47% |
| Herrik Shah | Promoter | 43.22% | 31.12% |
| Herrik Shah HUF | Promoter Group | 7.32% | — |
| Shrenik Shah | Promoter | 32.73% | 23.56% |
| Shrenik Shah HUF | Promoter Group | 4.09% | — |
| Pallavi Shah | Promoter | 4.70% | 3.38% |
| Mitali Shah | Promoter | 1.02% | 0.73% |
| Herrik Mountbaton Shah | Promoter | 43.22% | — |
| Shrenik Shah | Promoter | 32.73% | — |
| Pallavi Shah | Promoter | 4.70% | — |
| Herrik Mountbaton Shah HUF | Promoter Group | 7.32% | — |
| Shrenik Mountbaton Shah HUF | Promoter Group | 4.09% | — |
| Mitali Shah | Promoter Group | 1.02% | — |
Leadership
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.